Calculation of dose intensity and comparison of published methods using a cohort of canine T-cell lymphoma patients undergoing CHOP-based chemotherapy

Vet Comp Oncol. 2023 Jun;21(2):339-348. doi: 10.1111/vco.12894. Epub 2023 Mar 27.

Abstract

Methods of calculating and reporting dose intensity (DI) of CHOP-based protocols in the veterinary literature vary. The goal of this retrospective study is to examine the prognostic significance of the average percentage of planned DI received in a cohort of canine T-cell lymphoma patients treated with a modified CHOP protocol with corresponding toxicity and efficacy data. Our data set of 40 dogs was analysed using various previously published methods for calculating DI. Median progression-free survival and overall survival were 91 and 196 days, respectively. Receiving a higher percentage of planned DI was not found to be associated with patient outcome. Outcomes remain poor for dogs with T-cell lymphoma treated with CHOP-based chemotherapy irrespective of received DI. Standard methods of DI calculation and reporting should be adopted in veterinary oncology to enable repeatable and rigorous comparisons of published chemotherapy protocols and to ascertain the potential prognostic relevance of DI in canine lymphoma patients.

Keywords: chemotherapy; dog.

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols
  • Cyclophosphamide
  • Dog Diseases*
  • Dogs
  • Doxorubicin
  • Lymphoma, T-Cell* / drug therapy
  • Lymphoma, T-Cell* / veterinary
  • Prednisone / therapeutic use
  • Prognosis
  • Retrospective Studies
  • Vincristine

Substances

  • Prednisone
  • Vincristine
  • Cyclophosphamide
  • Doxorubicin